All Articles

Annaly Capital's consistent dividend payout raises key questions about strategy, risk, and the future of the mortgage REIT sector. What does it signal?

Early trial data suggests GRI-0621 could be a game-changer for Idiopathic Pulmonary Fibrosis, showing lung repair and a much better safety profile.

T1 Energy is raising massive capital for its G2_Austin plant and to comply with federal rules, betting big on an American-made clean energy supply chain.

BridgeBio Oncology's new drug candidate BBO-10203 could redefine cancer therapy by avoiding a key toxicity, unlocking a vast market.

With a 2026 launch looming, Nuvalent adds a proven oncology dealmaker to its board, signaling a strategic pivot from R&D to market assault.

Fintech firm Nayax's oversubscribed Israeli offering signals strong investor confidence and fuels its ambitious plan for global expansion through acquisitions.

Aardvark Therapeutics' pivotal trial for Prader-Willi syndrome goes global, a key step toward commercializing its novel hunger-suppressing drug.

A new partnership bundles advanced CAM software with CNC machines, promising to eliminate integration bottlenecks and accelerate productivity on the shop floor.

Four Points Technology’s top AWS award reveals a powerful strategy combining elite tech skills with unique federal contracting advantages. Here’s what it means.

A 91% strike vote at a NS nursing home reveals deep wage gaps and a staffing crisis, placing the future of elder care at a perilous crossroads.

How empowering 4,500 employees with $100 each transformed corporate giving, creating a wave of support for 2,100 charities nationwide.

With shareholder approval, TowneBank's acquisition of Dogwood reshapes the regional banking landscape. What's next for customers, competitors, and investors?

A small biotech is challenging oncology's giants with a drug that targets cancer's core weakness, offering new hope to the sickest lung cancer patients.

Micro-cap BSEG racks up awards against giants like Variety, but with a volatile stock and weak fundamentals, can creative success spark a financial turnaround?

Atlantica's latest acquisition is more than just megawatts; it's a calculated move to capture Canada's green energy boom and secure long-term growth.

A new report shows slow progress on fixing ERs and long-term care, raising questions about government accountability and the real-world cost to Ontarians.

How a bold $100M pandemic-era investment in a NYC landmark defied market gloom, achieving 100% occupancy and setting a new standard for office resilience.

Canada adds four groups to its terror list, taking a bold stand against online networks preying on youth and global insurgencies. Here's what it means.

A $2M non-dilutive facility is helping Luminit scale its holographic optics production, a key move to dominate the booming AR-HUD market in auto and defense.

Vision Fortune Finance Institute unveils a powerful new data engine for its Nexus AI, aiming to revolutionize financial research by taming data overload.